Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents

European Journal of Heart Failure

Volumn 6, Issue 4, 2004, Pages 377-387

  Šimůnek, Tomáš ^a   Klimtová, Ivona ^a   Kaplanová, Jana ^b   Mazurová, Yvona ^c   Adamcová, Michaela ^c   Štěrba, Martin ^c   Hrdina, Radomír ^a   Geršl, Vladimír ^c  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Animal model; Cardiomyopathy; Cardiotoxicity; Daunorubicin; Dexrazoxane; Heart failure

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; PROTECTIVE AGENT; RAZOXANE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CHEMICAL ANALYSIS; CONTROLLED STUDY; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEMODYNAMIC MONITORING; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BODY WEIGHT; CARDIOVASCULAR AGENTS; DAUNORUBICIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ERYTHROCYTE INDICES; HEART FAILURE, CONGESTIVE; HEART RATE; HEART VENTRICLES; MALE; MODELS, CARDIOVASCULAR; MYOCARDIUM; MYOCYTES, CARDIAC; RABBITS; RAZOXANE; STROKE VOLUME; TIME FACTORS;

EID: 2942618622     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2003.05.003     Document Type: Article

References (38)

1. Teerlink J.R., Goldhaber S.Z., Pfeffer M.A. An overview of contemporary etiologies of congestive heart failure. Am Heart J. 121:1991;1852-1853
2. Feenstra J., Grobbee D.E., Remme W.J., Stricker B.H. Drug-induced heart failure. J Am Coll Cardiol. 33:1999;1152-1162
3. Gharib M.I., Burnett A.K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 4:2002;235-242
4. Tan C., Tasaka H., Yu K.P., Murphy M.L., Karnofsky D.A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 20:1967;333-353
5. Hrdina R., Gersl V., Klimtova I., et al. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove). 43:2000;75-82
6. Hale J.P., Lewis I.J. Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child. 71:1994;457-462
7. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 339:1998;900-905
8. Fisher N.G., Marshall A.J. Anthracycline-induced cardiomyopathy. Postgrad Med J. 75:1999;265-268
9. Hasinoff B.B., Hellmann K., Herman E.H., Ferrans V.J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem. 5:1998;1-28
10. Wiseman L.R., Spencer C.M. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs. 56:1998;385-403
11. Swain S.M., Whaley F.S., Gerber M.C., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 15:1997;1318-1332
12. Herman E.H., Ferrans V.J. Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity. Prog Pediatr Cardiol. 8:1998;49-58
13. Herman E.H., Ferrans V.J. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol. 25:(4 Suppl 10):1998;15-21
14. Maral R., Bourat G., Ducrot R., et al. Toxicologic study and experimental antitumor activity of rubidomycin. Pathol Biol. 15:1967;903-908
15. Van Vleet J.F., Ferrans V.J. Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res. 41:1980;1462-1469
16. Teraoka K., Hirano M., Yamaguchi K., Yamashina A. Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail. 2:2000;373-378
17. Vaynblat M., Shah H.R., Bhaskaran D., et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 4:2002;583-586
18. Bertani T., Poggi A., Pozzoni R., et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest. 46:1982;16-23
19. Klimtova I., Simunek T., Mazurova Y., et al. Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. Hum Exp Toxicol. 21:2002;649-657
20. Pye M.P., Black M., Cobbe S.M. Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res. 31:1996;873-881
21. Pennock G.D., Yun D.D., Agarwal P.G., Spooner P.H., Goldman S. Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction. Am J Physiol. 273:1997;2018-2029
22. Gersl V, Hrdina R. Noninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1994;37:49-55
23. Chiron BV. Cardioxane product monograph. Amsterdam, The Netherlands, 1995
24. Zima T., Tesar V., Crkovska J., et al. ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats. Nephrol Dial Transplant. 13:1998;1975-1979
25. Herman E.H., el-Hage A., Ferrans V.J. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol. 92:1988;42-53
26. Meinardi M.T., van der Graaf W.T., van Veldhuisen D.J., et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 25:1999;237-247
27. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 62:1978;865-872
28. Jaenke R.S. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res. 36:1976;2958-2966
29. Cassidy S.C., Chan D.P., Rowland D.G., Allen H.D. Effects of doxorubicin on diastolic function, contractile reserve, and ventricular-vascular coupling in piglets. Pediatr Cardiol. 19:1998;450-457
30. max). Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1993;36:35-44
31. Ganong W.F. Review of medical physiology. 19th ed. 1997;542 Lange Medical Books, New York
32. Long H.J., Diamond S.S., Burningham R.A., Raflo C.P. Systolic time interval recordings in rabbits with congestive cardiomyopathy induced by chronic anthracycline administration. Am J Vet Res. 44:1983;1375-1377
33. Schoemaker R.G., Smits J.F. Systolic time intervals as indicators for cardiac function in rat models for heart failure. Eur Heart J. 11:(Suppl I):1990;114-123
34. Schott G. Systolic time intervals and echocardiography in monitoring adriamycin-treated tumor patients. Z Gesamte Inn Med. 46:1991;280-282
35. O'Brien P.J., Dameron G.W., Beck M.L., et al. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci. 47:1997;486-495
36. O'Brien P.J., Dameron G.W., Beck M.L., Brandt M. Differential reactivity of cardiac and skeletal muscle from various species in two generations of cardiac troponin-T immunoassays. Res Vet Sci. 65:1998;135-137
37. Herman E.H., Lipshultz S.E., Rifai N., et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 58:1998;195-197
38. Adamcova M., Gersl V., Hrdina R., et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol. 125:1999;268-274